S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

$80.91
0.00 (0.00 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$80.63
Now: $80.91▼
$81.87
50-Day Range
$75.19
MA: $78.61▼
$82.54
52-Week Range
$65.25
Now: $80.91▼
$92.64
Volume7.28 million shs
Average Volume11.49 million shs
Market Capitalization$204.64 billion
P/E Ratio19.73
Dividend Yield3.02%
Beta0.48
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Read More
Merck & Co., Inc. logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.14 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:MRK
Previous Symbol
CUSIP58933Y10
CIK310158
Webwww.merck.com
Phone908-740-4000

Debt

Debt-to-Equity Ratio0.94
Current Ratio1.32
Quick Ratio1.05

Price-To-Earnings

Trailing P/E Ratio19.73
Forward P/E Ratio14.17
P/E Growth2.11

Sales & Book Value

Annual Sales$46.84 billion
Price / Sales4.37
Cash Flow$6.68 per share
Price / Cash Flow12.11
Book Value$10.21 per share
Price / Book7.92

Profitability

EPS (Most Recent Fiscal Year)$5.19
Net Income$9.84 billion
Net Margins22.20%
Return on Equity52.94%
Return on Assets16.50%

Miscellaneous

Employees71,000
Outstanding Shares2,529,241,000
Market Cap$204.64 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$80.91
0.00 (0.00 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock been impacted by COVID-19 (Coronavirus)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 2.1% and is now trading at $80.91.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merck & Co., Inc.?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings data on Friday, July, 31st. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.14 by $0.23. The firm earned $10.87 billion during the quarter, compared to analysts' expectations of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The firm's quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.30 EPS.
View Merck & Co., Inc.'s earnings history.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Wednesday, July 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its board has approved a share repurchase plan on Thursday, October 25th 2018, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 5.1% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its stock is undervalued.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided EPS guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

What price target have analysts set for MRK?

14 analysts have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s share price to reach $94.93 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

Has Merck & Co., Inc. been receiving favorable news coverage?

Press coverage about MRK stock has trended neutral recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Merck & Co., Inc..

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
  • Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
  • Mr. Adam H. Schechter, Special Advisor (Age 54)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.50%), Macquarie Group Ltd. (0.46%), Swiss National Bank (0.43%), Fisher Asset Management LLC (0.36%), PNC Financial Services Group Inc. (0.36%) and LSV Asset Management (0.34%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, Bank of Nova Scotia, Thornburg Investment Management Inc., Victory Capital Management Inc., Menora Mivtachim Holdings LTD., Railway Pension Investments Ltd, Robeco Institutional Asset Management B.V., and DAVENPORT & Co LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was acquired by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Sumitomo Mitsui Trust Holdings Inc., Alecta Pensionsforsakring Omsesidigt, Candriam Luxembourg S.C.A., LSV Asset Management, Strs Ohio, Principal Financial Group Inc., and First Trust Advisors LP.
View insider buying and selling activity for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $80.91.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $204.64 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.